Top 5 Medical Apps on Android in New Zealand: Q3 2024 Performance

In the third quarter of 2024, the top medical apps on the Android platform in New Zealand displayed varied performance trends in terms of downloads, revenue, and active user engagement. Here's a closer look at how these apps fared, based on data from Sensor Tower.

Blood Sugar Diary for Diabetes saw a notable increase in weekly revenue, starting from about $29 in early July and peaking at approximately $179 by the end of September. Weekly downloads, however, showed a downward trend, dropping from 197 to 63 over the quarter. Despite this, the app maintained a relatively stable number of weekly active users, closing the quarter with around 207 users.

Afya Whitebook: Medicina maintained a steady revenue stream, averaging around $80 per week throughout the quarter. The app's active user base remained consistent, fluctuating slightly but ending the quarter with about 29 users. However, it experienced minimal downloads during this period.

The Monash University FODMAP diet app exhibited fluctuating revenue, with a high of $118 in late August and a low of $27 in mid-September. Downloads varied slightly, ranging from 6 to 13 weekly. Active users showed some variation but generally hovered around 340 to 399 throughout the quarter.

For the Sanford Guide, revenue remained relatively stable, averaging slightly above $50 per week. This app had minimal new downloads and no significant data on active users was available.

Lastly, My Calendar - Period Tracker experienced a slight decline in revenue, starting at $46 and ending at $34 weekly by the end of September. Downloads were initially strong at 200 but decreased over the quarter, finishing at 95. Despite these changes, the app maintained a robust active user base, with weekly users ranging from 5.2K to 6K.

These performance insights, sourced from Sensor Tower, highlight the dynamic nature of the medical app market in New Zealand. For more detailed analysis, Sensor Tower offers comprehensive data and insights.